Revance Therapeutics, Mylan’s collaboration partner for a proposed biosimilar version of Allergan’s Botox (onabotulinumtoxinA), will “step back and re-evaluate” the project if Mylan opts against continuing to participate in development, as the clock ticks on the firm’s decision.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?